Clinical Trial Detail

NCT ID NCT03735446
Title Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Cytarabine + Etoposide + Mitoxantrone + Prexasertib

Age Groups: senior adult

No variant requirements are available.